Since KV1.3 was first discovered in T-cells in 1984 (DeCoursey et al., 1984), the channel has been studied as a potential target for immunosuppression and immunomodulation in multiple sclerosis, autoimmune diabetes, rheumatoid arthritis, psoriasis and ulcerative colitis (Beeton et al., 2006; Kundu-Raychaudhuri et al., 2014; Unterweger et al., 2021). Here, KCNA3 is linked to psoriasis.